PRODUCTS AND SERVICES

  • 425 cancer-related genes – whole exons with significant introns
  • Comprehensive genomic profiling
    • Single nucleotide variant (SNV)
    • Copy number variation (CNV)
    • Small insertion/deletion (Indel)
    • Gene fusions and large genomic rearrangement (LGR)
    • Tumor mutation burden (TMB)
    • Microsatellite instability (MSI)
  • Applicable sample types: tumor tissues, fine needle biopsies and liquid biopsies (plasma, pleural effusion, cerebrospinal fluid, and urine)

Lung Cancer Testing


百迈康

Pulmocan®

Lung Cancer Testing

100% coverage of all exons and significant introns of 139 lung cancer related genes. Minimal sample requirement. Covers 67 molecular-targeted/chemo drugs and current clinical trials related to lung cancer. Pulmocan is minimally-invasive, supports dynamic monitoring of disease progression, prompts discovery of drug resistance which allows timely adjustments of treatment plans.

初得康

Tetradecan®

Lung Cancer Testing

100% coverage of all exons and significant introns of NCCN lung cancer guideline-recommended genes and related core genes of other pathways (14 genes in total). Minimal sample requirement, covers lung cancer related molecular targeted drugs and clinical trials.


Gastro-Intestinal Cancer Testing


斯达康

Stomocan®

Gastro-Intestinal Cancer Testing

100% coverage of all exons and significant introns of 50 stomach cancer related genes. Stomocan has minimal sample requirement, covers stomach cancer related molecular targeted/chemotherapy drugs and clinical trials, includes MSI testing which prompts stomach cancer prognosis, provides guidance to immunotherapies (PD-1/PD-L1), and prompts hereditary risks.

英泰康

Intescan®

Gastro-Intestinal Cancer Testing

100% coverage of all exons and significant introns of 45 intestinal cancer related genes. Intescan has minimal sample requirement, covers intestinal cancer related molecular targeted/chemotherapy drugs and clinical trials, includes MSI testing which prompts intestinal cancer prognosis, provides guidance to immunotherapies (PD-1/PD-L1) and post-operative auxiliary chemotherapies, and prompts hereditary risks.

利福康

Livocan®

Gastro-Intestinal Cancer Testing

100% coverage of all exons and significant introns of 41 liver/gallbladder cancer related genes. Livocan has minimal sample requirement, covers liver/gallbladder cancer related molecular targeted/chemotherapy drugs and clinical trials, and prompts hereditary risks.

盼可康

Pancrecan®

Gastro-Intestinal Cancer Testing

100% coverage of all exons and significant introns of 40 pancreas cancer related genes. Pancrecan has minimal sample requirement, covers pancreas cancer related molecular targeted/chemotherapy drugs and clinical trials, and prompts hereditary risks.

吉士康

Gistcan®

Gastro-Intestinal Cancer Testing

100% coverage of all exons and significant introns of 39 genes related to gastro-intestinal stromal tumor (GIST). Gistcan has minimal sample requirement, covers GIST-related molecular targeted/chemotherapy drugs and clinical trials, and prompts hereditary risks.

依福康

Esophacan®

Gastro-Intestinal Cancer Testing

100% coverage of all exons and significant introns of 53 genes related to esophageal cancer. Esophacan has minimal sample requirement, covers esophageal cancer related molecular targeted/chemotherapy drugs and clinical trials, tests for inactivating mutations of related MSI/MMR genes to comprehensively prompt hereditary risks.


Breast Cancer & Gynecological Cancer Testing


汝美康

Mamecan®

Breast Cancer & Gynecological Cancer Testing

100% coverage of all exons and significant introns of 48 breast cancer related genes. Mamecan has minimal sample requirement, covers breast cancer related molecular targeted/endocrinal/chemotherapy drugs and clinical trials, and prompts hereditary risks.

吉诺康

Gynocan®

Breast Cancer & Gynecological Cancer Testing

100% coverage of all exons and significant introns of 50 common gynecological cancer (ovarian/cervical/endometrial) related genes. Gynocan has minimal sample requirement, covers common gynecological cancer related molecular targeted/chemotherapy drugs and clinical trials, covers MSI-guided immunotherapies (PD-1/PD-L1, etc.) and comprehensively prompts hereditary risks.


Prostate Cancer & Urological Tumor Testing


普罗康

Proscan®

Prostate Cancer & Urological Tumor Testing

100% coverage of all exons and significant introns of 40 prostate cancer related genes. Proscan has minimal sample requirement, covers prostate cancer related molecular targeted/endocrinal/chemotherapy drugs and clinical trials, covers MSI testing and may be used to guide immunotherapies (PD-1/PD-L1).

优罗康

Urocan®

Prostate Cancer & Urological Tumor Testing

100% coverage of all exons and significant introns of 55 common urological tumors (kidney/bladder) related genes. Urocan has minimal sample requirement, covers common gynecological cancer related molecular targeted/chemotherapy drugs and clinical trials, covers MSI testing which may provide guidance to immunotherapies (PD-1/PD-L1, etc.) and comprehensively prompts hereditary risks.


Hematologic Malignancies Testing


血默胜

Hemasalus D/DR®

Hematologic Malignancies Testing

Recommended for patients with malignant neoplasms of the blood-lymphatic system, Hemasalus sequences 446 related DNA and total RNA which may come from a variety of sample types including blood, bone marrow, fresh tissue, FFPE, oral exfoliative cells, etc. Test results can be used to assist in clinical diagnosis of the disease as well as MRD testing, exploration of drug-resistance mechanisms, post-transplantation chimerism testing, ultimately guiding disease treatment enabling prognosis assessment.